Authors:
Ozcan, M
Morton, CT
Solovey, A
Dandelet, L
Bach, RR
Hebbel, RP
Slungaard, A
Key, NS
Citation: M. Ozcan et al., Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation, THROMB HAEM, 85(2), 2001, pp. 250-255
Citation: Mj. Page et al., Patient/caregiver assessment of convenience in the use of recombinant activated factor VII (rVIIa; NovoSeven (R)) in home therapy, BL COAG FIB, 11, 2000, pp. S51-S52
Authors:
Reding, MT
Wu, HY
Krampf, M
Okita, DK
Diethelm-Okita, BM
Christie, BA
Key, NS
Conti-Fine, BM
Citation: Mt. Reding et al., Sensitization of CD4(+) T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects, THROMB HAEM, 84(4), 2000, pp. 643-652
Authors:
Behl, R
Klein, MB
Dandelet, L
Bach, RR
Goodman, JL
Key, NS
Citation: R. Behl et al., Induction of tissue factor procoagulant activity in myelomonocytic cells inoculated by the agent of human granulocytic ehrlichiosis, THROMB HAEM, 83(1), 2000, pp. 114-118
Authors:
Thorland, EC
Drost, JB
Lusher, JM
Warrier, I
Shapiro, A
Koerper, MA
Dimichele, D
Westman, J
Key, NS
Sommer, SS
Citation: Ec. Thorland et al., Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk, HAEMOPHILIA, 5(2), 1999, pp. 101-105
Authors:
Reding, MT
Wu, H
Krampf, M
Okita, DK
Diethelm-Okita, BM
Key, NS
Conti-Fine, BM
Citation: Mt. Reding et al., CD4(+) T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects, THROMB HAEM, 82(2), 1999, pp. 509-515
Authors:
Key, NS
Aledort, LM
Beardsley, D
Cooper, HA
Davignon, G
Ewenstein, BM
Gilchrist, GS
Gill, JC
Glader, B
Hoots, WK
Kisker, CT
Lusher, JM
Rosenfield, CG
Shapiro, AD
Smith, H
Taft, E
Citation: Ns. Key et al., Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors, THROMB HAEM, 80(6), 1998, pp. 912-918